Skip to main content
TipRanks
Go Ultimate75% OFF

Accendra Health (ACH) AI Stock Analysis

570 Followers
ACH

Accendra Health

(NYSE:ACH)

Select Model
Rating:40Underperform
Price Target:$0.13â–¼(-5.30% Downside)
Action:downgraded
Date:11/14/26

The score is primarily held back by weak financial health (negative equity, ongoing losses, and renewed revenue decline) and very bearish technicals (price far below major moving averages with negative momentum). Partially offsetting these risks are improved recent cash generation and liquidity actions noted on the earnings call, but guidance was reduced materially, limiting confidence in a near-term turnaround.

Positive Factors
Improved Cash GenerationThe return to positive operating and free cash flow improves the company’s ability to fund operations internally and reduce reliance on external capital. Although cash generation remains volatile and modest relative to business scale, the rebound provides a more constructive base for executing the turnaround.
Negative Factors
Negative Stockholders’ EquityNegative equity weakens the capital structure and limits financial flexibility even though total debt is lower than in prior periods. It can also increase refinancing and credit risk, making the company more dependent on sustained cash generation and successful operational execution.

Accendra Health (ACH) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%ACH-95.43%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$10.15M
Dividend Yield
―
Average Volume (3M)
2.46M
Price to Earnings (P/E)
-0.1
Beta (1Y)
1.35
Revenue Growth
-61.96%
EPS Growth
87.15%
Country
US
Employees
6,500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Accendra Health Business Overview & Revenue Model

Company Description

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The P...

Accendra Health Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-55.70%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentNegative

The call had several constructive elements, including strong liquidity, debt reduction, progress on payer audits, an extended receivables facility, and a detailed turnaround plan with execution already underway. However, the overall tone was negative because third-quarter results were described as extremely disappointing, revenue declined, multiple categories remained weak, operating costs were elevated, and full-year adjusted EBITDA guidance was reduced by as much as 30% versus the prior midpoint.

Positive Updates

Strong Liquidity and Cash Management
Management said liquidity remains strong, with $27 million of cash, only $35 million drawn on the revolving credit facility, and nearly $300 million of available liquidity sources as of September 30. The company expects to have plenty of liquidity for the foreseeable future.

Negative Updates

Disappointing Third-Quarter Performance
Management described the quarter as extremely disappointing and said most near-term profit improvement efforts over the prior few months did not yield the expected results. The company acknowledged that it had significantly underperformed expectations in 2026.

Company Guidance

For the remainder of 2026, Accendra Health now believes full-year net revenue will be at the bottom of its previous guidance range of $2.45 billion-$2.55 billion, adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of the last adjusted EBITDA guidance provided, and adjusted EBITDA for Q4 is expected to be comparable to the third quarter; future CapEx will be quite a bit lower in 2027 than 2026, the company expects to share its outlook for 2027 early next year, and it expects to share further details, including expectations on the financial impact of the changes, in Q1 of 2027.

Accendra Health Financial Statement Overview

Summary

Operationally improving but still weak overall: revenue is down TTM (-3.6%) and earnings remain negative (net margin ~-6.7%). Free cash flow turned positive (~$121M TTM) and operating cash flow is positive (~$68M), but the balance sheet is a major risk with negative stockholders’ equity, limiting financial flexibility despite lower total debt versus 2024–2025.

Income Statement

34Negative

Balance Sheet

18Very Negative

Cash Flow

52Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.55B2.76B10.70B10.33B9.96B9.79B
Gross Profit1.13B1.29B2.22B2.13B1.83B1.51B
EBITDA141.09M219.75M51.22M390.57M368.45M415.46M
Net Income-171.56M-1.10B-362.69M-41.30M22.39M221.59M
Balance Sheet
Total Assets2.08B2.45B4.66B5.09B5.39B3.54B
Cash, Cash Equivalents and Short-Term Investments26.61M281.99M49.38M243.04M69.47M55.71M
Total Debt1.85B2.23B2.14B2.41B2.79B1.15B
Total Liabilities2.65B2.91B4.09B4.17B4.44B2.60B
Stockholders Equity-568.23M-460.98M565.23M924.17M945.60M938.50M
Cash Flow
Free Cash Flow-163.83M-303.12M-66.67M532.82M158.42M74.49M
Operating Cash Flow-25.31M-101.79M161.50M740.71M325.01M124.18M
Investing Cash Flow313.45M144.42M-116.53M-137.25M-1.80B-53.63M
Financing Cash Flow-307.79M188.08M-267.60M-417.33M1.50B-129.48M

Accendra Health Technical Analysis

Technical Analysis SentimentNegative
Last Price0.13

Price Trends

50DMA0.51Negative
100DMA1.51Negative
200DMA2.14Negative

Market Momentum

MACD-0.10Negative
RSI24.10Positive
STOCH6.13Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACH, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.51, and below the 200-day MA of 2.14, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 24.10 is Positive, neither overbought nor oversold. The STOCH value of 6.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACH.

Accendra Health Risk Analysis

Accendra Health disclosed 37 risk factors in its most recent earnings report. Accendra Health reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We have sold our P&HS business, and there may be negative impacts on our financial condition, results of operations, cash flows, capital resources and liquidity.Q4, 2025
2.In connection with the sale of the P&HS business, we are required to provide certain transitional services which may divert management's attention and harm our business.Q4, 2025
3.In connection with the sale of the P&HS business, we are receiving certain transitional services and are dependent on the successful execution of these services by a third party.Q4, 2025

Accendra Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ACH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MEDSMEDS40Underperform$3.34M-0.04356.14%―-77.47%62.15%
ACHACH40Underperform$10.16M-0.0633.56%―-61.96%87.15%
RDGTRDGT33Underperform$3.85M-0.00-3.54%―10.16%98.05%
YIYI33Underperform$24.95M-1.5923.64%―-23.90%-45.45%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%100%ACHRDGTAHGYIHKPDMEDSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ACH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ACHAccendra Health Inc0.13-2.76-95.43%
RDGTRidgetech, Inc.1.06-579.44-99.82%
AHGAkso Health Group Sponsored ADR1.24-0.13-9.49%
YI111, Inc.2.84-1.06-27.14%
HKPDHong Kong Pharma Digital Technology Holdings Ltd.1.62-21.98-93.14%
MEDSDatameds Ai, Inc.0.74-28.51-97.46%

Accendra Health Corporate Events

Business Operations and StrategyFinancial Disclosures

Accendra Health Reports Weak Third-Quarter Financial Results

Negative
Nov 5, 2026

On November 5, 2026, Accendra Health reported third-quarter results for continuing operations for the period ended September 30. Net revenue fell to $601.8 million from $697.3 million a year earlier, while the GAAP loss widened to $18.0 million from...

Executive/Board Changes

Accendra Health Executive Transitions to Strategic Advisor Role

Neutral
Nov 3, 2026

On October 29, 2026, Perry A. Bernocchi, the company’s executive vice president and chief operating officer, entered into a transition agreement concerning his move from executive officer duties to Strategic Advisor to the Chief Executive Officer. Th...

Business Operations and StrategyPrivate Placements and Financing

Accendra Health Extends $150 Million Receivables Program to 2029

Positive
Nov 2, 2026

On October 29, 2026, Accendra Funding LLC and Byram Healthcare Centers, wholly owned subsidiaries of Accendra Health, amended the company’s receivables purchase agreement. The amendment extended the $150 million receivables sale program’s scheduled t...

Delistings and Listing ChangesRegulatory Filings and Compliance

Accendra Health Outlines Plan to Regain NYSE Compliance

Negative
Oct 30, 2026

On October 27, 2026, Accendra Health received notice from the New York Stock Exchange that it was no longer in compliance with listing standards requiring both an average market capitalization and stockholders’ equity of at least $50 million over a 3...

Delistings and Listing ChangesShareholder MeetingsStock Split

Accendra Health Addresses NYSE Listing Price Deficiency

Negative
Oct 9, 2026

On October 6, 2026, Accendra Health received notice from the New York Stock Exchange that its common stock no longer met the exchange’s continued listing standard requiring an average closing price of at least $1 over a consecutive 30‑day trading per...

Business Operations and StrategyExecutive/Board Changes

Accendra Health appoints new CEO and commercial chief

Positive
Sep 17, 2026

On September 17, 2026, Accendra Health named board member Kenneth Gardner-Smith as its next President and Chief Executive Officer, with his transition into the role expected early in the fourth quarter of 2026. He will succeed long-serving CEO Edward...

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A Transactions

Accendra Health Halts Equity Program, Highlights Liquidity Strength

Positive
Aug 17, 2026

On August 17, 2026, Accendra Health announced it will not proceed with a planned at-the-market equity issuance program that was intended to modestly reduce debt, saying the decision, driven by market conditions, will not affect its results or guidanc...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026